967 related articles for article (PubMed ID: 19770628)
1. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Seo MD; Lee KW; Lim JH; Yi HG; Kim DY; Oh DY; Kim JH; Im SA; Kim TY; Lee JS; Bang YJ
Jpn J Clin Oncol; 2008 Sep; 38(9):589-95. PubMed ID: 18772169
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
12. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
[TBL] [Abstract][Full Text] [Related]
14. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
[TBL] [Abstract][Full Text] [Related]
15. Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.
Koucky K; Wein A; Konturek PC; Albrecht H; Reulbach U; Männlein G; Wolff K; Ostermeier N; Busse D; Golcher H; Schildberg C; Janka R; Hohenberger W; Hahn EG; Siebler J; Neurath MF; Boxberger F
Med Sci Monit; 2011 May; 17(5):CR248-58. PubMed ID: 21525806
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]